Zurex Pharma is a technology company.
Zurex Pharma has raised $19.0M across 3 funding rounds.
Zurex Pharma has raised $19.0M in total across 3 funding rounds.
Zurex Pharma has raised $19.0M in total across 3 funding rounds.
Zurex Pharma's investors include Baird Capital, InterWest.
Zurex Pharma, Inc. is a specialty pharmaceutical and medical technology company developing antimicrobial products to prevent healthcare-associated infections, particularly surgical site infections (SSIs) and catheter-related infections.[1][2][3][5] Its flagship product, ZuraGard, is an applicator-based skin antiseptic that delivers rapid microbial reduction with less irritation than standard chlorhexidine gluconate (CHG)/isopropyl alcohol solutions, featuring a patented one-handed hourglass design for efficiency.[1] Backed by private equity firm Baird Capital and listed in GCI's portfolio, the company—founded in 2010 and based in Middleton, Wisconsin—focuses on commercializing its novel platform amid rising antimicrobial resistance and infection prevention needs.[1][2][3]
Zurex Pharma was founded in 2010 in Middleton, Wisconsin, as a life sciences venture targeting gaps in antimicrobial technology for hospital settings.[3] While specific founders are not detailed in available sources, the company emerged to tackle scientific barriers in skin antisepsis, a key factor in preventing SSIs, which affect surgical outcomes.[1] Early development centered on its proprietary platform, leading to ZuraGard, validated in clinical trials for superior microbial kill and reduced prep time.[1] Pivotal traction came through private equity investment from Baird Capital, positioning it for commercialization in infectious disease prevention.[2]
Zurex Pharma rides the wave of antimicrobial resistance (AMR) and post-pandemic emphasis on hospital infection control, where SSIs impact millions annually and drive up healthcare costs.[1][5] Its timing aligns with regulatory pushes for innovative antisepsis amid rising resistant pathogens, positioning it favorably in the $10B+ infection prevention market.[4] By improving skin prep efficacy and usability, Zurex influences medtech standards, potentially reducing SSI rates and supporting broader ecosystem shifts toward preventive biotech solutions.[1][3]
Zurex Pharma is poised to expand its approved isopropyl alcohol-based products into broader SSI and bacterial infection applications, leveraging clinical data for new indications and partnerships.[4] Trends like AMR escalation and value-based care will amplify demand for its efficient, low-irritation platform, with private equity fueling commercialization.[2] Its influence may grow through portfolio diversification and potential acquisitions, solidifying its niche in medtech-pharma hybrids tackling healthcare's persistent infection challenges—echoing its core mission to redefine antisepsis.[1][5]
Zurex Pharma has raised $19.0M across 3 funding rounds. Most recently, it raised $9.0M Series D in June 2018.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Jun 1, 2018 | $9.0M Series D | Baird Capital, InterWest | |
| Jul 1, 2014 | $4.0M Series B | Baird Capital, InterWest | |
| May 1, 2012 | $6.0M Series A | Baird Capital, InterWest |